Protease inhibitor
Viral Evolution in Response to the Broad-Based Retroviral Protease Inhibitor TL-3
... a protease inhibitor developed using the feline immunodeficiency virus protease as a ...in protease and viral properties associated with resistance to TL-3, a panel of chronological in vitro ...
7
ISOLATION & CHARACTERIZATION OF PROTEASE INHIBITOR GENES FROM POTATO SOLANUM TUBEROSUM (L )
... 2005). Protease inhibitor and α-inhibitors serve as one of the defense mechanisms in plants against invading ...pests. Protease inhibitors are generally low molecular weight protein that make ...
16
Cysteine Protease Inhibitor (AcStefin) Is Required for Complete Cyst Formation of Acanthamoeba
... proteinase inhibitor in ...cysteine protease inhibitor (GenBank accession ...B. Protease activity (20 nM) only in the presence of substrates was considered 100%, and the percentages of ...
8
A Phase I/II Study of the Protease Inhibitor Indinavir in Children With HIV Infection
... Fifty-four HIV-infected children were enrolled be- tween July 1995 and August 1996, and the evaluation of the first 28 weeks on protocol is included in this report. The baseline patient characteristics for all children ...
11
Recovery of serine protease inhibitor from fish roes by polyethylene glycol precipitation
... the protease inhibitor was fractionated from fish eggs using methods based on protein solubility using organic solvent and ammonium sulfate ...the protease inhibitor was more effective than ...
8
Multicenter Quality Control of Hepatitis C Virus Protease Inhibitor Resistance Genotyping
... At the time this national quality control program was started, very few serum samples were available from patients who had been treated with a protease inhibitor and had experienced a viral breakthrough or ...
6
Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments
... multiple protease inhibitors in combination or in succession, mutation patterns of protease isolates from these persons have not been ...different protease inhibitor experiences: 1,004 ...
12
Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients
... a protease inhibi- tor containing regimen; and (ii) the first and second gen- otype performed showed complete absence followed by the presence of the primary protease inhibitor resistance ...
9
Regulation of factor XIa activity by platelets and alpha 1 protease inhibitor
... 1- protease inhibitor and Factor IX ...an inhibitor of Factor XIa, and to protect Factor XIa from inactivation in the presence of alpha 1-protease inhibitor and the secreted platelet ...
10
Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir
... nonpeptidic protease inhibitor of human immunodeficiency virus type 1 (HIV-1) with activity against clinical HIV-1 isolates from treatment-experienced ...with protease inhibitor-experienced ...
8
Evolution of Human Immunodeficiency Virus Type 1 Protease Genotypes and Phenotypes In Vivo under Selective Pressure of the Protease Inhibitor Ritonavir
... the protease inhibitor ritonavir (RTV) in ...transcriptase inhibitor therapy using a heteroduplex tracking assay designed to detect common resistance-associated ...the protease ...
12
An Aspartyl Protease Inhibitor Orthologue Expressed by Parelaphostrongylus tenuis Is Immunogenic in an Atypical Host
... aspartyl protease inhibitor from Onchocerca volvulus (GenBank P21250 ...aspartyl protease inhibitor (GenBank P19400 [26]) showed 19% identity to ...aspartyl protease inhibitors, the ...
8
Microglial activation decreases retention of the protease inhibitor saquinavir: implications for HIV treatment
... In addition to HIV, AIDS patients frequently suffer multiple bacterial and viral co-infections (for example, CNS toxoplasmosis, cryptococcosis, and tuberculosis) and are under a constant state of generalized brain ...
14
In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects.
... HIV-1 protease have become available and have shown some initial promise in clin- ical trials (5, 30, 41, ...Unfortunately, protease inhibitor-resistant variants of HIV-1 have appeared both during ...
6
Inactivation of Factor XIa by Plasma Protease Inhibitors: PREDOMINANT ROLE OF α1 PROTEASE INHIBITOR AND PROTECTIVE EFFECT OF HIGH MOLECULAR WEIGHT KININOGEN
... plasma protease that, by activating Factor IX, plays an important role in the early phase of the intrinsic pathway of blood ...plasma protease inhibitors, a 1 -protease inhibitor, antithrombin ...
10
Darunavir Resistance in HIV Infecting Protease Inhibitor Experienced Mexican Patients
... Background: Darunavir (DRV) is a useful antiretroviral treatment in the salvage therapy of multiclass-resistant HIV- infected patients. This study’s aim was to determine the frequency and risk factors for DRV ...
7
Characterization of a novel aspartyl protease inhibitor from Haemonchus contortus
... Background: Aspartyl protease inhibitor (API) was thought to protect intestinal parasitic nematodes from their hostile proteolytic environment. Studies on Ostertagia ostertagi, Ascaris suum and Brugia ...
9
Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients
... (HIV) protease in viral isolates from patients experiencing viral re- bound during protease inhibitor (PI) therapy often show the sequential accumulation of several mutations that produce changes in ...
8
Assessment of FIV C infection of cats as a function of treatment with the protease inhibitor, TL 3
... The protease inhibitor, TL-3, demonstrated broad efficacy against FIV, SIV and HIV in tissue culture [12], as well as against drug-resistant HIV isolates ...
12
SOLUBILITY ENHANCEMENT OF POORLY WATER SOLUBLE PROTEASE INHIBITOR
... ABSTRACT: There are more than 40% of drugs which are poorly soluble and 90% of the drugs from the pipeline are from BCS class II and IV. Application of techniques like computers, robotics, high-throughput screening, ...
7